Orforglipron (LY-3502970)
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Community Research
Join others researching Orforglipron — share findings, ask questions, and learn from real experiences
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
Molecular Data
Not applicable - synthetic small molecule Complex or non-standard sequence format
Research Indications
ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
91% achieved near-normal blood sugar levels versus 42% with placebo.
ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Dosing Protocols
Once-daily oral tablet requiring no reconstitution. Can be taken with or without food or water at any time of day.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Type 2 diabetes initiation | 3mg daily | Once daily, any time | Oral tablet |
| Type 2 diabetes moderate control | 12mg daily | Once daily, any time | Oral tablet |
| Type 2 diabetes optimal control | 36mg daily | Once daily, any time | Oral tablet |
| Weight loss initiation | 6mg daily | Once daily, any time | Oral tablet |
| Weight loss optimization | 36mg daily | Once daily, any time | Oral tablet |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
Stop Signs - Discontinue if:
- Severe or persistent abdominal pain radiating to back (potential pancreatitis)
- Neck lumps, hoarseness, difficulty swallowing, or neck swelling
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
- Suicidal thoughts, severe depression, or significant mood changes
- Vision changes or persistent eye pain
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
Quality Checklist
Good Signs
- Intact tablet packaging with proper labeling, batch numbers, and expiration dates
- Uniform tablet appearance without discoloration, chipping, or cracking
- Proper storage at room temperature (15-30°C)
Warning Signs
- As of late 2025, orforglipron remains investigational only; any product claiming FDA approval is fraudulent
Bad Signs
- Discolored, crumbling, or damaged tablets indicate improper storage
- Moisture exposure or humidity damage
References
- ATTAIN-1 Phase 3 Trial (Obesity)(2025)
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
- ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)(2025)
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)(2025)
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
- Phase 2 Obesity Study(2023)
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.